We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Goldshield Grp | LSE:GSD | London | Ordinary Share | GB0002893823 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 486.25 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:0359B Goldshield Group PLC 05 April 2006 Goldshield Group PLC SFO UPDATE The Serious Fraud Office has today charged Goldshield Group Plc ("Goldshield") in connection with its investigation into the market for the anti-coagulant drug, warfarin, in the period November 1996 to October 1999. Goldshield denies that it has acted in a way that was unlawful or improper and remains entirely confident that it will be acquitted of the charge against it. -ends- Date: 5 April 2006 For further information please contact: Goldshield Group plc City Profile Ajit Patel, Chief Executive Jonathan Gillen Rakesh Patel, Finance Director Tel: 020-8649-8500 Tel: 020-7448-3244 Web: www.goldshieldplc.com Mob: 07970-475659 This information is provided by RNS The company news service from the London Stock Exchange END MSCUUURGCUPQGPA
1 Year Goldshield Chart |
1 Month Goldshield Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions